# Evaluating Different Doses of Orelabrutinib in MCL

> **NCT05978739** · PHASE2 · UNKNOWN · sponsor: **InnoCare Pharma Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Orelabrutinib High dose
- **DRUG:** Orelabrutinib Low dose

## Key facts

- **NCT ID:** NCT05978739
- **Lead sponsor:** InnoCare Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-18
- **Primary completion:** 2025-02-25
- **Final completion:** 2025-05-25
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05978739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05978739, "Evaluating Different Doses of Orelabrutinib in MCL". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT05978739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*